AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10701474
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR 75-225 mg/day (n = 100)
Trial: 10701474
Drug: Fluoxetine 20-60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20-60 mg/day (n = 103)
Trial: 2110703
Drug: Haemophilus influenzae
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus influenzae type b polysaccharide‐protein conjugate vaccine (PRP‐D) mixed with meningococcal and/or pneumococcal capsular polysaccharide vaccines
Trial: 2110703
Drug: Halved vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halved vaccine dose
Trial: 2110703
Drug: Multiple vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple vaccine antigens
Trial: 760017
Drug: Cephradine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephradine (1 g preoperatively followed by 500 mg IV q. 6 hours for 4 doses)
Trial: 760017
Drug: Cephradine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephradine (2 g IV given approximately 1 hour before surgery)
Trial: 26514220
Drug: Subcutaneous local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous local analgesic infusion (ScLAI) with bupivacaine
Trial: 18488437
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with tiotropium
Trial: 17489939
Drug: Aminophylline infusion
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline infusion
Trial: 25468986
Drug: Subjects requesting
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects requesting antibiotics (overall comparison)
Trial: 20158291
Drug: Triazolam (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.125 mg/70 kg, oral)
Trial: 20158291
Drug: Triazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.25 mg/70 kg, oral)
Trial: 20158291
Drug: Scopolamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.25 mg/70 kg, subcutaneous)
Trial: 20158291
Drug: Scopolamine (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.50 mg/70 kg, subcutaneous)
Trial: 12422622
Drug: Aronia in
RxNorm normalized name: Aronia melanocarpa fruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aronia in combination with apple pectin (15 g of apple pectin and 20 ml of Aronia concentrate twice daily)
Trial: 1677212
Drug: L-threonine, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-threonine, dosage and duration not specified
Trial: 7037662
Drug: Pivampicillin (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin (350 mg, three times daily for 15 days)
Trial: 7037662
Drug: Ampicillin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (250 mg, three times daily for 15 days)
Trial: 30845690
Drug: Functional olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional olive oil (FOO, 487 ppm of phenolic compounds and enriched with 389 ppm of triterpenes)
Trial: 27841790
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo spray (saline spray)
Trial: 27841790
Drug: Lipid spray
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid spray (phosphatidylcholine; Tears again)
Trial: 27841790
Drug: Symptomatic wearers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic wearers with spray treatment
Trial: 26825840
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with or without radiation therapy (RT) (intravaginal or pelvic)
Trial: 26825840
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (intravaginal RT or pelvic RT) alone
Trial: 8092508
Drug: Eltanolone 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltanolone 0.6 mg/kg
Trial: 3046851
Drug: Cefodizime (CDZ)
RxNorm normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefodizime (CDZ) - 2 g daily dose i.v. for 6 days to patients and for 4 days to healthy subjects.
Trial: 30304237
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (50 mg/kg daily)
Trial: 28734717
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg twice a day for 7 days)
Trial: 28734717
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug (standard of care)
Trial: 21990307
Drug: 2.0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g/d ginger
Trial: 12956319
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (0.4 g x d(‐1))
Trial: 11831450
Drug: Inhaled formoterol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled formoterol, twice daily for 4 weeks
Trial: 31467052
Drug: New service
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New service delivery model including case management, counselling, AAC training, and AAC therapy.
Trial: 11309556
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg daily for 7 days
Trial: 9295896
Drug: Fraxiparine 3075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fraxiparine 3075 IU AXa (fixed dosage)
Trial: 9295896
Drug: Fraxiparine 4100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fraxiparine 4100 or 6150 IU AXa (dosage adjusted for body weight)
Trial: 8314476
Drug: Interferon alfa‐2b,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2b, 3 million units subcutaneously, thrice weekly for 12 months
Trial: 8314476
Drug: Interferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2b (12 months treatment)
Trial: 25925674
Drug: Colchicine (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (standard daily dose)
Trial: 22179917
Drug: 200 mcg
RxNorm normalized name: CrM 200 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg Misoprostol sublingually, 2 hours before diagnostic hysteroscopy
Trial: 22179917
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prior preparation)
Trial: 22179917
Drug: 200 mcg
RxNorm normalized name: CrM 200 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg Misoprostol sublingually, 2 hours before diagnostic hysteroscopy (in postmenopausal women)
Trial: 22179917
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prior preparation, in postmenopausal women)
Trial: 22179917
Drug: 200 mcg
RxNorm normalized name: CrM 200 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg Misoprostol sublingually, 2 hours before diagnostic hysteroscopy (in patients with a history of vaginal delivery)
Trial: 22179917
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prior preparation, in patients with a history of vaginal delivery)
Trial: 12858920
Drug: Rectal dihydroartemisinin
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal dihydroartemisinin (DATM)
Trial: 8807058
Drug: ZDV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZDV plus didanosine plus escalating doses (400 to 1,200 mg/day) of delavirdine (DLV) (group 2)
Trial: 8807058
Drug: 1,200 mg
RxNorm normalized name: lecithin 1,200 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg of DLV alone per day (group 3)
Trial: 8807058
Drug: ZDV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZDV plus 1,200 mg of DLV per day (group 4)
Trial: 6393814
Drug: Pirenzepine and
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine and antacids
Trial: 25210016
Drug: Ipilimumab retreatment
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab retreatment at 10 mg/kg
Trial: 25210016
Drug: Ipilimumab induction
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab induction at 0.3 mg/kg
Trial: 25210016
Drug: Ipilimumab induction
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab induction at 3 mg/kg
Trial: 25210016
Drug: Ipilimumab induction
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab induction at 10 mg/kg
Trial: 25210016
Drug: Ipilimumab induction
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab induction at 3 mg/kg (treatment-naive)
Trial: 25210016
Drug: Ipilimumab induction
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab induction at 10 mg/kg (treatment-naive)
Trial: 25210016
Drug: Ipilimumab retreatment
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab retreatment (0.3 mg/kg)
Trial: 25210016
Drug: Ipilimumab retreatment
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab retreatment (3 mg/kg)
Trial: 25210016
Drug: Ipilimumab retreatment
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab retreatment (10 mg/kg)
Trial: 17229252
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (other disease-modifying anti-rheumatic drug therapies)
Trial: 27889574
Drug: Budesonide Oral
RxNorm normalized name: budesonide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide Oral Suspension (BOS) 2 mg twice daily for 12 weeks
Trial: 10764435
Drug: NAC (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC (cisplatin 50 mg/m², vincristine 1 mg/m² for 1 day, bleomycin 25 mg/m² for 3 days for three cycles followed by radical hysterectomy
Trial: 1444609
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (40 mg weekly for 8 weeks, with two additional instillations every 15 days in 50 ml saline)
Trial: 1444609
Drug: Mitoxantrone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (20 mg weekly for 8 weeks, with two additional instillations every 15 days in 50 ml saline)
Trial: 2932307
Drug: Cleocin T
RxNorm normalized name: Cleocin T
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cleocin T Topical 1 percent Solution
Trial: 2932307
Drug: Cleocin T
RxNorm normalized name: Cleocin T
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cleocin T Topical 1 percent Lotion
Trial: 28663395
Drug: Femoral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral nerve block with 75 mg of 0.25% levobupivacaine hydrochloride
Trial: 28663395
Drug: Periarticular infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periarticular infiltration with 150 mg of 0.25% levobupivacaine hydrochloride, 10 mg morphine sulphate, 30 mg ketorolac trometamol, 0.25 mg of adrenaline diluted with 0.9% saline to 150 ml
Trial: 23474642
Drug: tele‐SEGT (supportive‐expressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tele‐SEGT (supportive‐expressive group therapy)
Trial: 19725253
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium (150 mg per day)
Trial: 17964975
Drug: Ibuprofen (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (7 mg/kg every 8 h)
Trial: 15094573
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine 1 mg/kg
Trial: 15094573
Drug: IV midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV midazolam 0.15 mg/kg
Trial: 15094573
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine 1 mg/kg plus IV midazolam 0.1 mg/kg
Trial: 15094573
Drug: IV midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV midazolam 0.1 mg/kg plus IV fentanyl 2 microg/kg
Trial: 15094573
Drug: IV propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV propofol 2 mg/kg
Trial: 11820726
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of bovine pancreatic chymotrypsin
Trial: 11820726
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of papain
Trial: 11820726
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of bacterial protease from Bacillus licheniformis
Trial: 11820726
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Alcalase
Trial: 11820726
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Optimase
Trial: 11820726
Drug: Occluded application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occluded application of aqueous enzyme solution
Trial: 11820726
Drug: Two-step unoccluded
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two-step unoccluded application of aqueous enzyme solution followed by commercial moisturizer
Trial: 9428539
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN group; n = 56)
Trial: 4758487
Drug: Low nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low nicotine cigarettes (<0.3 mg)
Trial: 4758487
Drug: High nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High nicotine cigarettes (3.2 mg)
Trial: 25847690
Drug: DM-1992 (extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DM-1992 (extended-release carbidopa/levodopa), 2 times per day
Trial: 25847690
Drug: CD/L-dopa IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD/L-dopa IR (immediate-release carbidopa/levodopa), 4.8 times per day
Trial: 25847690
Drug: CD/L-dopa IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD/L-dopa IR
Trial: 19654956
Drug: Oral uridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral uridine
Trial: 16740612
Drug: Systemic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic administration of intravenous terbutaline (TRB)
Trial: 16740612
Drug: Forearm blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forearm blood flow (FBF) response to incremental doses of isoprenaline
Trial: 11227395
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 to 20 mg/day
Trial: 11227395
Drug: Risperidone 4
RxNorm normalized name: risperidone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 4 to 12 mg/day
Trial: 9024451
Drug: Prednisone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (4 mg/kg per day)
Trial: 8420726
Drug: Cimetidine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (n = 65) as an iv infusion of 50 to 100 mg/hr
Trial: 6981177
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) intravenously for at least four days or orally for at least nine days (total daily dose, 10-20 mg/kg)
Trial: 6981177
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) therapy
Trial: 6981177
Drug: Initial intravenous
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial intravenous therapy with doses of 15-20 mg/kg per day
Trial: 28109298
Drug: Intravenous G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous G-CSF followed by mPBMC infusion
Trial: 28109298
Drug: Intravenous G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous G-CSF followed by mPBMC infusion at 7 months (T7 group)
Trial: 28109298
Drug: Intravenous G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous G-CSF followed by mPBMC infusion at 1 month (T1 group)
Trial: 28109298
Drug: mPBMC infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mPBMC infusion
Trial: 24554302
Drug: Prulifloxacin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prulifloxacin (600 mg once a week for 12 weeks)
Trial: 24554302
Drug: Fosfomycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin (3 g once a week for 12 weeks)
Trial: 21636230
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with clarithromycin (200mg/day) and S-carboxymethylcysteine (1500mg/day) for 12 weeks
Trial: 21636230
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with clarithromycin (200mg/day) for 12 weeks
Trial: 21636230
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with clarithromycin and S-carboxymethylcysteine
Trial: 21636230
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (combination and monotherapy)
Trial: 19489132
Drug: 200 mcg
RxNorm normalized name: CrM 200 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg HFA-BDP bid for 12 weeks
Trial: 19489132
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg CFC-BDP bid for 12 weeks
Trial: 17407649
Drug: DPP-4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitors as monotherapy
Trial: 17407649
Drug: DPP-4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitors as add-on therapy
Trial: 12780372
Drug: NRT (nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRT (nicotine replacement therapy)
Trial: 8936558
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of vitamin E per day
Trial: 8936558
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of vitamin C per day
Trial: 6193665
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of dextran 1, 15% administered intravenously two minutes before infusion of dextran 70 or dextran 40
Trial: 6193665
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of dextran 1, 15%
Trial: 28421567
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment (28 tablets of 1000 µg cyanocobalamin per month)
Trial: 28421567
Drug: Intramuscular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular treatment (four weekly injections of 1000 µg hydroxocobalamin)
Trial: 28421567
Drug: Intramuscular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular treatment